-anib
An angiogenesis inhibitor, blocking the growth of new blood vessels that tumours need.
- Drugs ending in -anib: 28
- Approved somewhere: 5
- With a US drug page: 4
- Stem
- -anib
- Class
- Drugs that stop tumours growing new blood vessels
- Most common targets
- Vascular endothelial growth factor receptor (12), KIT (7), PDGFRA, PDGFRB (7), CSF1R (3), Fibroblast growth factor receptor (3), KDR (3), FGFR1 (2), VEGFA (2)
Approved and clinical-stage drugs in ChEMBL whose names ending in -anib, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Pazopanib | Approved | CSF1R, KIT, LCK, FGFR3 and 4 more | Macrophage colony stimulating factor receptor inhibitor |
| Pegaptanib sodium | Approved | VEGFA | Vascular endothelial growth factor A antagonist |
| Tivozanib | Approved | Vascular endothelial growth factor receptor, KIT, PDGFRB | Vascular endothelial growth factor receptor inhibitor |
| Vandetanib | Approved | SRC, PTK6, TEK, Vascular endothelial growth factor receptor and 3 more | Tyrosine-protein kinase SRC inhibitor |
| Nintedanib | Approved | PDGFRA, PDGFRB, Vascular endothelial growth factor receptor, Fibroblast growth factor receptor | Platelet-derived growth factor receptor inhibitor |
| Beloranib | Phase 3 | METAP2 | Methionine aminopeptidase 2 inhibitor |
| Bevasiranib | Phase 3 | VEGF-A mRNA, TLR3 | VEGF-A mRNA RNAi inhibitor |
| Brivanib | Phase 3 | Fibroblast growth factor receptor, Vascular endothelial growth factor receptor | Fibroblast growth factor receptor inhibitor |
| Brivanib alaninate | Phase 3 | Fibroblast growth factor receptor, Vascular endothelial growth factor receptor | Fibroblast growth factor receptor inhibitor |
| Cediranib | Phase 3 | KIT, PDGFRA, PDGFRB, Vascular endothelial growth factor receptor | Stem cell growth factor receptor inhibitor |
| Crenolanib | Phase 3 | PDGFRA, PDGFRB, FLT3 | Platelet-derived growth factor receptor inhibitor |
| Linifanib | Phase 3 | CSF1R, FLT3, PDGFRA, PDGFRB, Vascular endothelial growth factor receptor | Macrophage colony stimulating factor receptor inhibitor |
| Motesanib | Phase 3 | KIT, RET, Vascular endothelial growth factor receptor, PDGFRA, PDGFRB | Stem cell growth factor receptor inhibitor |
| Pegaptanib octasodium | Phase 3 | VEGFA | Vascular endothelial growth factor A inhibitor |
| Pegpleranib sodium | Phase 3 | PDGFB | Platelet-derived growth factor subunit B inhibitor |
| Rivoceranib | Phase 3 | KDR | Vascular endothelial growth factor receptor 2 inhibitor |
| Semaxanib | Phase 3 | KIT, Vascular endothelial growth factor receptor | Stem cell growth factor receptor inhibitor |
| Trebananib | Phase 3 | ANGPT1, ANGPT2 | Angiopoietin-1 inhibitor |
| Vatalanib | Phase 3 | KIT, PDGFRA, PDGFRB, Vascular endothelial growth factor receptor, CSF1R | Stem cell growth factor receptor inhibitor |
| Foslinanib | Phase 2 | — | — |
| Lucitanib | Phase 2 | FGFR1, Vascular endothelial growth factor receptor, FGFR2 | Fibroblast growth factor receptor 1 inhibitor |
| Pegdinetanib | Phase 2 | KDR | Vascular endothelial growth factor receptor 2 inhibitor |
| Risuteganib | Phase 2 | — | — |
| Vorolanib | Phase 2 | — | — |
| Alofanib | Phase 1 | — | — |
| Migaldendranib | Phase 1 | — | — |
| Necuparanib | Phase 1 | — | — |
| Toceranib | — | KDR, PDGFRB, KIT | receptor protein-tyrosine kinase inhibitor |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO